Histological Subtype Impacts Survival in Renal Cell Cancer

This article originally appeared here.
Share this content:
Histological Subtype Impacts Survival in Renal Cell Cancer
Histological Subtype Impacts Survival in Renal Cell Cancer

(HealthDay News) – The histological subtype of renal cell carcinoma (RCC) impacts both overall and cancer-specific survival, according to a study published in the August issue of The Journal of Urology.

Kirk A. Keegan, MD, of the Vanderbilt University School of Medicine in Nashville, Tenn., and colleagues conducted a large, population-based cohort study using data from the National Cancer Institute's Surveillance, Epidemiology and End Results database involving 17,605 patients who underwent surgery for RCC from 2000 to 2005. The authors sought to determine the role of RCC histopathology on the stage-specific survival rate.

The researchers found that, compared to that among patients with clear cell histology, presentation with T3 or greater disease was less likely among patients with papillary and chromophobe pathology (17.6 and 16.9%, respectively) and more likely among patients with collecting duct and sarcomatoid variants (55.7 and 82.8%, respectively). Histology correlated significantly with overall and cancer-specific survival on multivariate analysis; improved survival was seen for patients with the chromophobe pathology (hazard ratio, 0.56), while patients with collecting duct or sarcomatoid variants had worse survival (hazard ratios, 2.07 and 2.26, respectively).

"Histological subtype in patients with RCC predicts overall and cancer-specific survival. Despite adjustment for stage, patients with collecting duct and sarcomatoid RCC variants have poor survival," the authors write. "These findings may inform the role of percutaneous renal biopsy and other pretreatment diagnostic techniques since differences in histology reflect intrinsic biological variance and may ultimately form the basis of future targeted therapy."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs